In Brief This Week: Pacific Biosciences; Epigenomics; Cynvenio Biosystems; and More | GenomeWeb

NEW YORK (GenomeWeb) — Pacific Biosciences announced this week that it has reached the final developmental milestone of its commercialization and licensing agreement with Roche. The agreement, originally announced in September, entitles Roche to commercialize and sell clinical diagnostics products developed by PacBio based on the company's Single Molecule, Real Time technology. With the final milestone achieved, Roche has paid PacBio an additional $20 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.